09939.HK
Kintor Pharmaceutical Limited
HKSE · Healthcare · Biotechnology · CN
HKD 1.82
−3.70%Price chart
Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18
Key dataSep 18, 2026
OpenHKD 1.89
From 52W high−60.61%
Volume875000.00
Market capHKD 840.12M
P/E (TTM)—
P/S (TTM)9.3x
Div yield—
Key dataSep 18, 2026
Open
HKD 1.89
From 52W high
−60.61%
Volume
875000.00
Market cap
HKD 840.12M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−5.2x
P/E (TTM)
—
RSI (14)
49.1
MomentumView details →
1D Return
−3.70%
YTD Return
−7.14%
Similar companies
Latest newsMore news →
Kintor Pharmaceutical announced on September 4, 2026 that its self-developed tyrosinase inhibitor KT-939 successfully completed a human long-term safety trial, with no skin adverse reactions observed in 114 subjects over 52 weeks of topical use, and the company is advancing registration with China's National Medical Products Administration.14d agoKintor Pharmaceutical reported interim results for the six months ended June 2026, with revenue of RMB 52.04 million, up about 7.7 times year-on-year, and a narrowed net loss of RMB 75.782 million from RMB 83.268 million a year earlier.32d ago